Posts Tagged ‘drugs’

Is It Time To Put A Fork In The BATFE?

Watch the video below too.  In this case, felony murder rules would not likely apply because there was no intent. It sounds more like "Project Gunwalker" was a disasterous plan from the beginning that worked out, not surprisingly, disasterously. – Ilene 

Courtesy of Karl Denninger, The Market Ticker 

I’ve been following the Project Gunwalker story for a while.

For those who are not familiar with it, the story line is this: The BATFE, that’s right – the Federal Government - has been intentionally allowing "straw sales" of rifles and pistols to go through and then letting those guns be transported to Mexico.

These are sales where the person doing the buying isn’t the actual intended owner of the weapon.  These guns are often bought in bulk, many at a time.  It’s not illegal to buy a lot of guns, even all at once, but it is a felony to buy them for someone else.

Anyway, BATFE was allegedly allowing this to go on and approving sales they knew were bogus.  Starting in 2009 several gun stores started getting suspicious – they were having people come in and paying with cash – sometimes with cash in paper bags – for multiple guns at once.  Specifically, it is alleged that over five hundred AK-47 semi-automatic rifles and over 2,500 weapons in total, including rifles and pistols, were purchased in this manner.

The claim is made that the BATFE literally watched the sales happen, each checked through NICS’ "background check", each approved, despite being alerted by the gun store owners that the sales were suspicious. 

The stores were told to proceed with the sales intentionally.

Let me repeat this: The allegation is that the BATFE intentionally allowed these weapons to be purchased despite knowing they were fraudulent straw purchases and then allowed them to be unlawfully transported into Mexico where they were delivered to various Mexican outlaws – including drug gangs.

Remember, we’ve been told that a lot of guns that Mexican drug lords are using are coming from the US?  Well, no kidding, they are, if this allegation is correct: Our own government was knowingly allowing them to be purchased and illegally transported across the border.

That’s bad.

What’s worse is this:

Then, Border Patrol Agent Brian Terry was murdered. The serial numbers on the two assault rifles found at the scene matched two rifles ATF watched Jaime Avila buy in Phoenix nearly a year before. Officials won’t answer whether the bullet that killed


continue reading


Tags: , , , , , , , , , ,




Fever to Harness RNA Interference Cools – NYTimes.com

Drugmakers’ Fever for the Power of RNA Interference Has Cooled

By ANDREW POLLACK

When RNA interference first electrified biologists several years ago, pharmaceutical companies rushed to harness what looked like a swift and surefire way to develop new drugs.

Billions of dollars later, however, some of those same companies are now losing their enthusiasm for RNAi, as it is called. And that is raising doubts about how quickly, if at all, the Nobel Prize-winning technique for turning off specific genes will yield the promised bounty of innovative medicines.

The biggest bombshell was dropped in November, when the Swiss pharmaceutical giant Roche said it would end its efforts to develop drugs using RNAi, after it had invested half a billion dollars in the field over four years.

Just last week, as part of a broader research cutback, Pfizer decided to shut down its 100-person unit working on RNAi and related technologies. Abbott Laboratories has also quietly shelved its RNAi drug development work.

“In 2005 and 2006, there was a very sudden buildup of expectation that RNAi was going to cure many diseases in a very short time frame,” said Dr. Johannes Fruehauf, vice president for research at Aura Biosciences, a small company pursuing the field. “Some of the hype, I believe, is going away and a more realistic view is setting in.”

The issue is that while drugs working through the RNAi mechanism can indeed shut off genes, it has been difficult to deliver such drugs to the cells where they are needed. At a time when hard-pressed pharmaceutical companies are already scaling back research expenditures, RNAi is losing out to alternatives that seem closer to producing marketable drugs.

“I have no doubt that at a certain point in time RNAi will make it to the market,” said Klaus Stein, head of therapeutic modalities for Roche. But he added, “When we looked into this, we came to the conclusion that we have opportunities that have higher priorities.”

More here: Fever to Harness RNA Interference Cools – NYTimes.com.


Tags: , , , ,




Who Should Take Statins? The Debate Continues

Who Should Take Statins? The Debate Continues

By Alice Park, courtesy of TIME 

It is well known that the cholesterol-lowering drugs called statins can reduce the risk of heart attack among people who already have heart disease. But whether the medications can prevent a heart attack from occurring in the first place is still a hotly contested question among health experts.

Two new studies published on Monday in the Archives of Internal Medicine reignite the simmering debate.

One study revisits the merits of the controversial Jupiter trial (or Justification for the Use of Statins in Primary Prevention), which was published in 2008 in the New England Journal of Medicine. That trial concluded that the statin drug Crestor (rosuvastatin) lowered the combined risks of heart attack, stroke, other heart events or heart-related death by 47% in healthy patients with no history of heart problems or high cholesterol but high levels of C-reactive protein (CRP), a marker for inflammation. The findings prompted the Food and Drug Administration in February to expand the eligible patient population for Crestor by millions.

Critics of the Jupiter trial have contended that the benefits of the cholesterol drug may have been exaggerated because the trial was stopped early — after two years, instead of the planned five. Had the trial been allowed to continue, critics say, the differences in benefit between the treatment and placebo groups may have disappeared. That is the argument raised again by the new study in the Archives, by an international group of scientists led by Dr. Michel de Lorgeril at the University Joseph Fourier and the National Center of Scientific Research in Grenoble, France.

Jupiter was stopped prematurely when an independent monitoring board gleaned an overwhelming treatment benefit in the statin group. Although the early termination of randomized and blinded control studies is common — to ensure the safety of patients, study leaders frequently monitor the accruing data and stop the trial when one group shows a predetermined amount of benefit over the other — in Jupiter’s case, de Lorgeril’s group argues, the study never made clear what the predetermined benefit was.

What the data did show, however, is that when certain hard clinical endpoints — such as heart-related death — were considered, the difference between the two groups was not significant enough to warrant stopping the trial. Among the entire study population of more than 17,000, there was a total of only 240…
continue reading


Tags: , , , , ,




Pharmboy Takes On Lilly

Here’s Pharmboy’s first stock and options recommendation for the new year, or decade. He’s generally bullish on Lilly and presents two strategies – a simple buy/write strategy and a slightly more complicated strategy which includes selling puts and calls. - Ilene  

Pharmboy Takes On Lilly

Courtesy of Pharmboy

Another year has come and gone, 2010 (twenty ten or two thousand ten – which do you prefer?) is here. The market is great for some, and a baffling experience for others. One thing we do know is that we all need, at some point, health care in one form or another! This year, my write-ups may focus on longer term strategies so that we don’t have to manage our trades on a daily basis. This means a bit more depth in the analysis of companies we invest in, and perhaps some longer term picks.

So, here we go for Pharmboy’s first segment for a new decade!

Eli Lilly (LLY) – is a global pharmaceutical company and is a member of the Fortune 500.  Its global headquarters is located in Indianapolis, Indiana.  The company was founded in 1876 by a pharmaceutical chemist, Eli Lilly, after whom the company was ultimately named. The company’s first innovation was changing the flavorings of medicines so that they were easier to take. The business grew and in 2008, had of $20Billion.

Among the company’s major pharmaceutical breakthroughs are: cephalosporin (antibiotic), erythromycin (antibiotic), insulin, and fluoxetine (Prozac). Among other distinctions, Lilly is the world’s largest manufacturer and distributor of medications used in a broad range of psychiatric and mental health-related conditions, including clinical depression, generalized anxiety disorder, narcotic addiction, insomnia, bipolar disorder, schizophrenia, and others. Below is a list of their brands: 

Cancer
Cardiology
Cardiology/Pulmonary
Diabetes
Byetta® (exenatide) injection
Diabetic Peripheral Neuropathic Pain (DPNP)
Erectile Dysfunction
Prozac Linked to Suicide Attempts and Violence

Fibromyalgia
Growth Disorders


continue reading


Tags: , , , , , ,




Crazymaker: Journal of American Media and Lifestyle

Fun post for the evening, by Charles Hugh Smith, in case you missed it earlier. – Ilene

Crazymaker: Journal of American Media and Lifestyle

Courtesy of Charles Hugh Smith, Of Two Minds

If you wonder why our society is so schizophrenic--look no further than Crazymaker Journal.

I happened upon a fascinating new online publication: Crazymaker, the Journal of American Media and Lifestyle. I have to say the content set me back on my heels; rarely do I see such an honest portrayal of the carefully mixed messages dished out as "news" and "entertainment".

crazymaker journal

Gregory Bateson addressed how a cognitive "double bind" could create a schizophrenic state of anxiety and dysfunction.

Their findings indicated that the tangles in communication often diagnosed as schizophrenia are not necessarily result of an organic brain dysfunction. Instead, they found that destructive double binds were a frequent pattern of communication among families of patients, and they proposed that growing up amidst perpetual double binds could lead to learned patterns of confusion in thinking and communication.

Human communication is complex; 90% of it is nonverbal (see also Albert Mehrabian) and context is an essential part of it. Communication consists of the words said, tone of voice, and body language. It also includes how these relate to what has been said in the past; what is not said, but is implied; how these are modified by other nonverbal cues, such as the environment in which it is said, and so forth.

For example, if someone says "I love you," one takes into account who is saying it, their tone of voice and body language, and the context in which it is said. It may be a declaration of passion or a serene reaffirmation, insincere and/or manipulative, an implied demand for a response, a joke, its public or private context may affect its meaning, and so forth.

This is an apt description of the craziness created by media/marketing messages every minute of every hour of every day in the USA. Bake a super-rich cake, and oh my, why are you so fat? Now you have to torture yourself with diets which don’t work.

Girls: want to look hot and sexy? if you don’t, you’re a loathesome loser.

Guys: not ripped with bulging muscles? Too bad--you’re a loathesome loser, too. Image and exteriors are everything!

The media profits from selling marketing/adverts. Marketing
continue reading


Tags: , , , , , , , , , ,




 
 
 

Zero Hedge

Iran's Supreme Leader Says Trump Will "Vanish From History" In Response To Pompeo's "12 Requirements"

Courtesy of ZeroHedge. View original post here.

Iran's leadership heightened its rhetoric in response to Secretary of State Mike Pompeo's bellicose speech given at the Heritage Foundation in which he outlined 12 "basic requirements" issued to Iran in the wake of Trump's pulling the US from the 2015 nuclear deal.

Pompeo's list included demands that Iran withdraw from Syria, release all US citizens, stop enrichment of uranium, end support for anti-Saudi Houthi fighters in Yemen, and allow "unqua...



more from Tyler

Digital Currencies

How the US Government Could Effectively Use Crypto

The US government could start, or officially endorse an existing crytpo coin. What they would do is build a fee into the software protocol that went to a single address that they control. This is effectively a tax. The fee could be a transaction fee, a percentage of the next block award, or a combination of both. How this works is every single transaction that occurs everywhere wihtin the system, the fee scalped goes directly to this single address that is owned by the IRS, in this case, the "New-IRS." Forget postcards. We're down to a single dude in one office chair in front of one computer. Imagine that being the IRS, because that's where this is going. The consequences of this mechanism are dramatic. First off the IRS is now one guy. Granted, this guy controls the private key for the most valuable thing in the world. This key would be the single most important key right up there with the nuclear launch code, but the system would most definitely still work. More strikingly, the US...

more from Bitcoin

Phil's Favorites

New Animal Spirits: What it takes to be wealthy

 

New Animal Spirits: What it takes to be wealthy

Courtesy of 

Michael and Ben’s new episode of Animal Spirits is out today, and it’s awesome as usual. If this isn’t part of your weekly routine yet, I don’t even know what to tell you at this point. No one is covering more interesting topics and blowing up like this podcast is.

This week’s topics:

  • Are Jack Bogle and Vanguard actually underrated?
  • Why closet indexing will never die.
  • Why money is flowing out of growth funds even though they’ve outperformed. ...


more from Ilene

Insider Scoop

Benzinga's Daily Biotech Pulse: Insmed Presents Data, Pfenex Pulls Back On Offering, Oncolytics Listing

Courtesy of Benzinga.

Related IBB Benzinga's Daily Biotech Pulse: Melinta, Ardelyx Pull Back On Offerings, Insys Awaits FDA Verdict ...

http://www.insidercow.com/ more from Insider

Chart School

Wide Market Cycle Review

Courtesy of Read the Ticker.

Lets review some big market cycles, to see where cycle pressure is building or peaking.

Cycles are like long term trend lines and are great for the long term view, of course price action leads (Wyckoff Logic) before cycles.

Lets go ...

US 10 yr: Trending higher to 4% ... Ouch. Inflation moving from Wall Street to Main Street.

Click for popup. Clear your browser cache if image is not showing.



The EURO looks to bottom (USD topping).

Click for popup. Clear your browser cache if image is not showing.



SSEC looks forward to another pump up to save the SP...

more from Chart School

Biotech

Could this be the year for a Canadian Breakthrough Prize in Life Sciences?

Reminder: Pharmboy is available to chat with Members, comments are found below each post.

 

Could this be the year for a Canadian Breakthrough Prize in Life Sciences?

Courtesy of John Bergeron, McGill University

In 2013, Kyoto University’s Shinya Yamanaka was awarded one of the first Breakthrough Prizes in Life Sciences for his discovery of “induced” stem cells that enabled researchers to convert adult cells back into stem cells.

The Breakthrough Prize is not to be sneezed at. Founded in 2013, the prize “honours transformative advances toward understanding living systems and extending human life.” It’s also the most financially attractive aw...



more from Biotech

ValueWalk

Buffett At His Best

By csinvesting. Originally published at ValueWalk.

Bear with me as I share a bit of my history that helped me create SkyVu and the Battle Bears games. The University of Nebraska gave me my first job after college. I mostly pushed TV carts around, edited videos for professors or the occasional speaker event. One day, Warren Buffet came to campus to speak to the College of Business. I didn’t think much of this speech at the time but I saved it for some reason. 15 years later, as a founder of my own company, I watch and listen to this particular speech every year to remind myself of the fundamentals and values Mr. Buffett looks for. He’s addressing business students at his alma mater, so I think his style here is a bit more ‘close to home’ than in his other speeches. Hopefully many of you find great value in this video like I have. Sorry for the VHS...



more from ValueWalk

Kimble Charting Solutions

The Stock Bull Market Stops Here!

 

The Stock Bull Market Stops Here!

Courtesy of Kimble Charting

 

The definition of a bull market or bull trends widely vary. One of the more common criteria for bull markets is determined by the asset being above or below its 200 day moving average.

In my humble opinion, each index above remains in a bull trend, as triple support (200-day moving averages, 2-year rising support lines, and February lows) are still in play ...



more from Kimble C.S.

Members' Corner

Cambridge Analytica and the 2016 Election: What you need to know (updated)

 

"If you want to fundamentally reshape society, you first have to break it." ~ Christopher Wylie

[Interview: Cambridge Analytica whistleblower: 'We spent $1m harvesting millions of Facebook profiles' – video]

"You’ve probably heard by now that Cambridge Analytica, which is backed by the borderline-psychotic Mercer family and was formerly chaired by Steve Bannon, had a decisive role in manipulating voters on a one-by-one basis – using their own personal data to push them toward voting ...



more from Our Members

Mapping The Market

The tricks propagandists use to beat science

Via Jean-Luc

How propagandist beat science – they did it for the tobacco industry and now it's in favor of the energy companies:

The tricks propagandists use to beat science

The original tobacco strategy involved several lines of attack. One of these was to fund research that supported the industry and then publish only the results that fit the required narrative. “For instance, in 1954 the TIRC distributed a pamphlet entitled ‘A Scientific Perspective on the Cigarette Controversy’ to nearly 200,000 doctors, journalists, and policy-makers, in which they emphasized favorable research and questioned results supporting the contrary view,” say Weatherall and co, who call this approach biased production.

A second approach promoted independent research that happened to support ...



more from M.T.M.

OpTrader

Swing trading portfolio - week of September 11th, 2017

Reminder: OpTrader is available to chat with Members, comments are found below each post.

 

This post is for all our live virtual trade ideas and daily comments. Please click on "comments" below to follow our live discussion. All of our current  trades are listed in the spreadsheet below, with entry price (1/2 in and All in), and exit prices (1/3 out, 2/3 out, and All out).

We also indicate our stop, which is most of the time the "5 day moving average". All trades, unless indicated, are front-month ATM options. 

Please feel free to participate in the discussion and ask any questions you might have about this virtual portfolio, by clicking on the "comments" link right below.

To learn more about the swing trading virtual portfolio (strategy, performance, FAQ, etc.), please click here ...



more from OpTrader

Promotions

NewsWare: Watch Today's Webinar!

 

We have a great guest at today's webinar!

Bill Olsen from NewsWare will be giving us a fun and lively demonstration of the advantages that real-time news provides. NewsWare is a market intelligence tool for news. In today's data driven markets, it is truly beneficial to have a tool that delivers access to the professional sources where you can obtain the facts in real time.

Join our webinar, free, it's open to all. 

Just click here at 1 pm est and join in!

[For more information on NewsWare, click here. For a list of prices: NewsWar...



more from Promotions

All About Trends

Mid-Day Update

Reminder: Harlan is available to chat with Members, comments are found below each post.

Click here for the full report.




To learn more, sign up for David's free newsletter and receive the free report from All About Trends - "How To Outperform 90% Of Wall Street With Just $500 A Week." Tell David PSW sent you. - Ilene...

more from David





About Phil:

Philip R. Davis is a founder Phil's Stock World, a stock and options trading site that teaches the art of options trading to newcomers and devises advanced strategies for expert traders...

Learn more About Phil >>


As Seen On:




About Ilene:

Ilene is editor and affiliate program coordinator for PSW. She manages the site market shadows, archives, more. Contact Ilene to learn about our affiliate and content sharing programs.

Market Shadows >>